Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820666 | 1.00 | PLA2G2C (0.46) | PLA2G2CCA2MAPK1ALDH1A1CA1 | |
| SCHEMBL16762206 | 1.00 | PLA2G2C (0.46) | PLA2G2CCA2MAPK1ALDH1A1CA1 | |
| SCHEMBL3884103 | 0.92 | PLA2G2C (0.47) | PLA2G2CPLA2G10MEN1KMT2AASAH1 | |
| SCHEMBL7639204 | 0.92 | PLA2G2C (0.47) | PLA2G2CPLA2G10MEN1KMT2AASAH1 | |
| SCHEMBL3888142 | 0.92 | PLA2G2C (0.47) | PLA2G2CPLA2G10MEN1KMT2AASAH1 | |
| SCHEMBL7549777 | 0.92 | PLA2G2C (0.47) | PLA2G2CPLA2G10MEN1KMT2AASAH1 | |
| SCHEMBL11050261 | 0.92 | PLA2G2C (0.47) | PLA2G2CPLA2G10MEN1KMT2AASAH1 | |
| SCHEMBL4284741 | 0.87 | CNR1 (0.41) | CNR2 | |
| SCHEMBL22722955 | 0.86 | PLA2G2C (0.49) | PLA2G2CCA2MAPK1CA1PLA2G10 | |
| SCHEMBL22722954 | 0.86 | PLA2G2C (0.49) | PLA2G2CCA2MAPK1CA1PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3507276-B1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11124487-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1465862-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1411933-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | PLA2G2C 827/4885CA2 1064/4885MAPK1 75/4885 |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | PLA2G2C 3193/4885CA2 1505/4885MAPK1 3949/4885 |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | PLA2G2C 1914/4885CA2 1576/4885MAPK1 3912/4885 |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | PLA2G2C 1914/4885CA2 1576/4885MAPK1 3912/4885 |
| US-11124487-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | PLA2G2C 1938/4885CA2 4092/4885MAPK1 1174/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | PLA2G2C 1914/4885CA2 1576/4885MAPK1 3912/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | PLA2G2C 2794/4885CA2 523/4885MAPK1 1640/4885 |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | PLA2G2C 3418/4885CA2 931/4885MAPK1 3649/4885 |
| US-11827609-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885 |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, SLC40A1, GPX4 | PLA2G2C 3014/4885CA2 1427/4885MAPK1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.